amiodarone has been researched along with Chronic Kidney Diseases in 5 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function." | 7.11 | Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. ( Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J, 2022) |
| "Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function." | 3.11 | Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial. ( Calkins, H; Hohnloser, SH; Lip, GYH; Ludwigs, U; Nam, GB; Oldgren, J; Stewart, J; Ueng, KC; Vamos, M; Wieloch, M; Zhu, J, 2022) |
| "In total, 3252 Chronic Renal Insufficiency Cohort participants with at least one study electrocardiogram between 2003 and 2011 were included." | 1.46 | Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. ( Delafontaine, P; Deo, R; Doerfler, RM; Fink, JC; Fischer, MJ; Jaar, BG; Kramlik, S; Makos, GK; Navaneethan, S; Ojo, A; Slaven, A; Snitker, S; Soliman, EZ; St Peter, WL; Weir, MR; Zhan, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vamos, M | 1 |
| Oldgren, J | 1 |
| Nam, GB | 1 |
| Lip, GYH | 1 |
| Calkins, H | 1 |
| Zhu, J | 1 |
| Ueng, KC | 1 |
| Ludwigs, U | 1 |
| Wieloch, M | 1 |
| Stewart, J | 1 |
| Hohnloser, SH | 1 |
| Ceynowa-Sielawko, B | 1 |
| Wybraniec, MT | 1 |
| Topp-Zielińska, A | 1 |
| Maciąg, A | 1 |
| Miśkowiec, D | 1 |
| Balsam, P | 1 |
| Wójcik, M | 1 |
| Wróbel, W | 1 |
| Farkowski, MM | 1 |
| Ćwiek-Rębowska, E | 1 |
| Ozierański, K | 1 |
| Błaszczyk, R | 1 |
| Bula, K | 1 |
| Dembowski, T | 1 |
| Peller, M | 1 |
| Krzowski, B | 1 |
| Wańha, W | 1 |
| Koziński, M | 1 |
| Kasprzak, JD | 1 |
| Szwed, H | 1 |
| Mizia-Stec, K | 1 |
| Szołkiewicz, M | 1 |
| Snitker, S | 1 |
| Doerfler, RM | 1 |
| Soliman, EZ | 1 |
| Deo, R | 1 |
| St Peter, WL | 1 |
| Kramlik, S | 1 |
| Fischer, MJ | 1 |
| Navaneethan, S | 1 |
| Delafontaine, P | 1 |
| Jaar, BG | 1 |
| Ojo, A | 1 |
| Makos, GK | 1 |
| Slaven, A | 1 |
| Weir, MR | 1 |
| Zhan, M | 1 |
| Fink, JC | 1 |
| Rao, DA | 1 |
| Lakdawala, NK | 1 |
| Miller, AL | 1 |
| Loscalzo, J | 1 |
| Nouri, SN | 1 |
| Block, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)[NCT00174785] | Phase 3 | 4,628 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 63 |
| Placebo | 90 |
The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 65 |
| Placebo | 94 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 116 |
| Placebo | 139 |
The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 675 |
| Placebo | 859 |
The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 734 |
| Placebo | 917 |
1 trial available for amiodarone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.
Topics: Amiodarone; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Dronedarone; Humans; Kidney; R | 2022 |
4 other studies available for amiodarone and Chronic Kidney Diseases
| Article | Year |
|---|---|
Pharmacological Cardioversion in Patients with Recent-Onset Atrial Fibrillation and Chronic Kidney Disease Subanalysis of the CANT II Study.
Topics: Amiodarone; Antazoline; Anti-Arrhythmia Agents; Atrial Fibrillation; Electric Countershock; Female; | 2022 |
Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Citalopram; Diab | 2017 |
Clinical problem-solving. In the thick of it.
Topics: alpha-Galactosidase; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomegaly; Codon, N | 2013 |
Triple Oral Antithrombotic Therapy: A Teachable Moment.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Chest Pain; Coronary Artery Disease; Drug-Elu | 2016 |